Arising from: R. L. Batterham et al. Nature 418, 650–654 (2002); Batterham et al. reply
Batterham et al. report that the gut peptide hormone PYY3–36 decreases food intake and body-weight gain in rodents1, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al.1 cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3–36.
Subscribe to Journal
Get full journal access for 1 year
only $3.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Batterham, R. L. et al. Nature 418, 650–654 (2002).
Halford J. C. et al. Pharmacol. Biochem. Behav. 61, 159–168 (1998).
Kanatani, A. et al. Endocrinology 141, 1011–1016 (2000).
Allen, J. M. et al. Digestion 30, 255–262 (1984).
Amersham Biosciences, RPNQ0085, Neuropeptide Y SPA binding assay (Y2).
Halatchev, I. G. et al. Endocrinology 145, 2585–2590 (2004).
Challis, B. G. et al. Biochem. Biophys. Res. Commun. 311, 915–919 (2003).
Challis, B. G. et al. Proc. Natl Acad. Sci. USA 101, 4695–4700 (2004).
Asakawa, A. et al. Gastroenterology 124, 1325–1336 (2003).
Nordheim, U. & Hofbauer, K. G. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R138–R142 (2004).
Several of the authors consult with, and have received financial support from, companies and institutions, including pharmaceutical firms, that may have active programmes relating to PYY3–36 of which we are not aware. Several of these companies have obesity-treatment development programmes and may therefore, from some perspectives, be considered competitors to companies pursuing PYY3–36.
About this article
Cite this article
Tschöp, M., Castañeda, T., Joost, H. et al. Does gut hormone PYY3–36 decrease food intake in rodents?. Nature 430, 1–3 (2004). https://doi.org/10.1038/nature02665
Expert Opinion on Investigational Drugs (2020)
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands
Pharmacology & Therapeutics (2019)
Modified Peptide YY Molecule Attenuates the Activity of NPY/AgRP Neurons and Reduces Food Intake in Male Mice
Journal of Clinical Investigation (2019)
The effect of breakfast with different macronutrient composition on PYY, ghrelin, and ad libitum intake 4 h after breakfast in Indonesian obese women
BMC Research Notes (2018)